This week's View explores the efficacy and safety outcomes for new-generation drug-eluting stents compared with bare-metal stents, the effects of beta-blockers and calcium antagonists on clinical outcomes in stable coronary artery disease, and a recent update on clinical trials of losartan with and without beta-blockers to block aneurysm growth in patients with Marfan syndrome.

Subscribe on iTunes | Subscribe on Google Play

Keywords: EaglesEyeView, Acute Coronary Syndrome, Adrenergic beta-Antagonists, Aneurysm, Dissecting, Angiotensin Receptor Antagonists, Aortic Aneurysm, Aortic Aneurysm, Thoracic, Aortic Diseases, Blood Pressure, Calcium Channel Blockers, Chest Pain, Coronary Angiography, Coronary Artery Bypass, Coronary Artery Disease, Coronary Stenosis, Dilatation, Drug-Eluting Stents, Extracellular Matrix, Heart Defects, Congenital, Hydralazine, Hypertension, Losartan, Marfan Syndrome, Muscle, Smooth, Vascular, Myocardial Infarction, Myocardial Ischemia, Myocardial Revascularization, Myocytes, Smooth Muscle, Outcome Assessment, Health Care, Percutaneous Coronary Intervention, Primary Prevention, Risk, Risk Factors, Secondary Prevention, Stents, Thrombosis, Transforming Growth Factors, Vascular Diseases, Cardiac Surgical Procedures, Pediatrics, Coronary Angiography, Diagnostic Imaging

< Back to Listings